NEW YORK (GenomeWeb News) – Ohio State University today announced it has licensed to Microlin Bio almost 100 issued and pending microRNA patents for the potential development of cancer diagnostics and treatments.

Microlin also licensed a novel nucleic acid delivery technology from OSU to deliver new therapies to cancer patients. The new therapies would be based on the miRNA patents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene regulation changes linked to human brain evolution, and more.

The New York Stem Cell Foundation's Initiative on Women in Science and Engineering working group presents seven strategies to promote gender equality in the sciences.

Researchers link a genetic variation to the ability to quickly process arsenic in people living in the Andes Mountains.

A small portion of pregnant women who've undergone non-invasive prenatal testing have found out from the test that they have cancer.